Volume 1.31 | Nov 23

Pancreatic Cell News 1.31, November 23, 2010.

TOP STORY 

Deletion of Protein Kinase C-Delta in Mice Modulates Stability of Inflammatory Genes and Protects Against Cytokine-Stimulated Beta Cell Death In Vitro and In Vivo  ShareThis
Researchers addressed the role of the protein kinase C (PKC) isoform PKC-delta, a diverse regulator of cell death, in cytokine-stimulated apoptosis in primary beta cells. [Diabetologia]

MesenCult®-XF Medium  
Culture Human Mesenchymal Stem Cells in
Xeno-Free MesenCult®-XF

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 


SPECIAL FEATURES 

Interested in recruiting talented individuals? Post your career opportunities in Pancreatic Cell News at no cost. Contact us at [email protected]

Follow us on Twitter! @PancreaticCell

SCIENCE NEWS

Enzyme Action Could Be Target for Diabetes, Heart Disease Treatments
Cardiac researchers have found a new cellular pathway that could help in developing therapeutic treatments for obesity-related disorders, like diabetes and heart disease. [Press release from the University of Cincinnati discussing research presented at the American Heart Association’s Scientific Sessions 2010]
 
Fetal Programming in Diabetes
Babies born to women who have high blood sugar (gestational diabetes) during pregnancy face a greater risk for developing obesity and Type 2 diabetes later on. Although elevated blood sugar levels can be mild for diabetic mothers who take precautions, the excess glucose crossing the placenta into their babies may seriously affect the pancreatic beta cells. [University of Arizona Press Release]

hESC-CD34_645x110_v01

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

DIABETES

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on Beta Cell Function in Individuals with Impaired Glucose Metabolism
Researchers hypothesized that ectopic fat deposition, in particular pancreatic fat accumulation, is related to beta cell dysfunction in individuals with impaired fasting glucose and/or impaired glucose tolerance. [J Clin Endocrinol Metab]
 
Fibroblast Populated Collagen Matrix Promotes Islet Survival and Reduces the Number of Islets Required for Diabetes Reversal
Investigators developed a fibroblast populated collagen matrix as a novel scaffold to improve islet cell viability and function post-transplantation. [J Cell Physiol]

A Biophysical Model of Electrical Activity in Human Beta Cells
This work presents the first mathematical model of electrical activity based entirely on published ion channel characteristics of human beta cells. The model reproduces satisfactorily a series of experimentally observed patterns in human beta cells, such as spiking and rapid bursting electrical activity, and their response to a range of ion channel antagonists. [Biophys J]
 
Interaction of Glibenclamide and Metformin at the Level of Translation in Pancreatic Beta Cells
Metformin activates AMP activated protein kinase in beta cells leading to suppression of protein translation through mammalian target of rapamycin (mTOR)-dependent and -independent signaling. Glibenclamide antagonizes these metformin-effects through activation of mTOR- and protein kinase A-dependent signaling. [J Endocrinol]

PANCREATIC CANCER


Ligand-Mediated Highly Effective and Selective C-N Coupling for Synthesizing Bioactive N-Aryltriazole Acyclonucleosides
Two synthesized nucleosides showed superior anticancer activity against drug-resistant pancreatic cancer, compared to the reference drug gemcitabine. [Org Lett]
 
Neoadjuvant Therapy Is Associated with Improved Survival in Resectable Pancreatic Adenocarcinoma
The authors’ objective was to compare long-term outcomes in patients receiving neoadjuvant versus adjuvant therapy for resectable pancreatic adenocarcinoma. [Cancer]
 
Low Extracellular pH Induces Damage in the Pancreatic Acinar Cell by Enhancing Calcium Signaling
Findings suggest that enhanced ryanodine receptor-mediated Ca2+ signaling in the basolateral region of the acinar cell is responsible for the injurious effects of low extracellular pH on the exocrine pancreas
[J Biol Chem]
 
Application of Human Pancreatic Carcinoid BON Cells for Receptor-Targeted Drug Development
Findings suggest that appropriately defined tumor cell lines may provide physiologically relevant cell-based evaluations of novel peptide analogs and receptor-targeted chemotherapeutics. [J Drug Target]
 
Loss of Raf-1 Kinase Inhibitory Protein in Pancreatic Ductal Adenocarcinoma
Results strongly suggest that Raf-1 kinase inhibitor protein is a metastasis suppressor in pancreatic ductal adenocarcinoma. [Pathology]
 
Knockdown of microRNA-21 Inhibits Proliferation and Increases Cell Death by Targeting Programmed Cell Death 4 (PDCD4) in Pancreatic Ductal Adenocarcinoma
Researchers examined the expression of a panel of five microRNAs (miRNA) in pancreatic ductal adenocarcinoma (PDAC) and the functional effect of miR-21 inhibition in PDAC cell lines. [J Gastrointest Surg]


INDUSTRY NEWS

Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals Partner to Investigate Metreleptin as Potential Therapy to Improve Blood Glucose Control in Type 1 Diabetes
The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. [Amylin Pharmaceuticals, Inc. Press Release]
 
DiaMedica Announces Research Collaboration with The Sanford Project, a Leading Type 1 Diabetes Research Center
DiaMedica Inc. announced the commencement of a research collaboration with The Sanford Project, a world leader in type 1 diabetes research. [DiaMedica Inc. Press Release]
 
Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, with University of California, San Francisco
Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. [Pfizer Inc. Press Release]
 
American Pharmacists Association Foundation Joins the Bristol-Myers Squibb Foundation’s $100 Million National Diabetes Initiative
The American Pharmacists Association Foundation announced it has been selected as an initial grantee in and will play a major role in the new Together on Diabetes®: Communities Uniting to Meet America’s Diabetes Challenge. [American Pharmacists Association Foundation Press Release]
 
Major Gift from Judy and J. John Goodman Supports Scripps Florida
The Scripps Research Institute has announced a $50,000 gift from Palm Beach residents Judy and J. John Goodman, M.D., to Scripps Florida. The gift will support both the work of Professor Thomas Kodadek in the development of a new approach to detect and treat Type I diabetes, as well as the Scripps Research graduate program endowment. [The Scripps Research Institute Press Release]
 
Oramed Pharmaceuticals Presents Results of Its Phase IIb Clinical Trial at the Diabetes Technology Meeting
Oramed Pharmaceuticals Inc. presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double blind study conducted in 29 patients with type 2 diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. [Oramed Pharmaceuticals Inc. Press Release]

Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from a retrospective study of nearly 375,000 type 2 diabetes patients evaluating the incidence of events related to cardiovascular disease and all-cause hospitalizations among initiators of BYETTA® (exenatide) injection compared to initiators of other commonly used diabetes medications. [Amylin Pharmaceuticals, Inc. Press Release]
 
Neogenix Oncology® Receives Patent for Its Monoclonal Antibody, 16C3, for Colorectal and Pancreatic Cancer
Neogenix Oncology, Inc. announced that the U.S. Patent and Trademark Office has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company’s monoclonal antibody for colorectal and pancreatic cancer. [Business Wire]
 
AVEO’s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-Tumor Activity and Safety in Advanced GI Cancers
AVEO Pharmaceuticals, Inc. announced results from a Phase Ib clinical trial evaluating the company’s lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers. [AVEO Pharmaceuticals, Inc. Press Release]
 
Follow-Up Data from Threshold Pharmaceuticals’ Phase I/II Clinical Trials of TH-302 Demonstrate Broad Activity in All Combinations Against Multiple Tumor Types
Threshold Pharmaceuticals, Inc. announced clinical trial results related to Threshold’s clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. [Threshold Pharmaceuticals, Inc. Press Release]
 
New National Surgical Centre for Pancreatic Cancer at St. Vincent’s Hospital
The Minister for Health and Children officially opened the new Health Service Executive National Cancer Control Program National Surgical Centre for Pancreatic Cancer at St. Vincent’s University Hospital, Dublin. [Health Service Executive Press Release]
 
Pancreatic Cancer UK Launches Study for Survival — The UK’s First Comprehensive Mapping of the Views and Experiences of People Living with and Treating Pancreatic Cancer
Pancreatic Cancer UK, launched Study for Survival, which is the UK’s first comprehensive mapping of the views and experiences of people living and working with pancreatic cancer. [Pancreatic Cancer UK Press Release]
 
The United States of Diabetes: New Report Shows Half the Country Could Have Diabetes or Prediabetes at a Cost of $3.35 Trillion by 2020
More than 50 percent of Americans could have diabetes or prediabetes by 2020 at a cost of $3.35 trillion over the next decade if current trends continue, according to new analysis by UnitedHealth Group’s Center for Health Reform and Modernization, but there are also practical solutions for slowing the trend. [UnitedHealth Group Press Release]
 
Joint IDF-CDS Study Reveals Impact of Diabetes in China
The International Diabetes Federation (IDF) and the Chinese Diabetes Society of the Chinese Medical Association (CDS) launched the findings of a new study revealing the social and economic impact of diabetes in China. [International Diabetes Federation Press Release]

POLICY NEWS

European Research Body to Get New Head
The European Research Council (ERC) is about to get a new leader, although not in the form most people expected. Helga Nowotny, chair of the ERC’s Scientific Council, a new secretary-general has been chosen to replace Andreu Mas-Colell, who stepped down for personal reasons in September. [European Research Council, European Union]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)
 
Medicines and Healthcare Products Regulatory Agency (United Kingdom)
 
Therapeutic Goods Administration (Australia)

EVENTS (Listed by Date)

Pharmacology in Stem Cells Research and Regenerative Medicine
December 17, 2010
London, United Kingdom

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction
January 12-17, 2011
Dillon, United States

Keystone Symposia: Obesity
January 12-17, 2011
Keystone, United States

2011 Gastrointestinal Cancers Symposium
January 20-22, 2011
San Francisco, United States

Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, D.C., United States

Early Development for Innovative Diabetes & Metabolic Syndrome Therapeutics Conference
January 26-27, 2011
Amsterdam, The Netherlands

Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club
February 10-13, 2011
Maradu, India

2nd Annual International Diabetes Summit
February 22-24, 2011
Dubai, United Arab Emirates

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

13th Annual C21 BioVentures
May 24-26, 2011
Napa, United States

European Pancreatic Club Meeting 2011
June 22-25, 2011
Magdeburg, Germany

PancreasFest 2011
July 28-30, 2011
Pittsburgh, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit
here  to post your career opportunities.



Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

 
forwardafriendicon
 
Comments or Suggestions? Email info[email protected] with your feedback.



Learn more about Pancreatic Cell News: Archives | Events | Contact Us